Digest Réseau Comment ça marche
Réseau
/
Sociétés
Tr
Non vérifié

Tris Pharma, Inc.

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté

15 communiqués de presse

Voir tous les communiqués de presse
09/12/2025
Industrie
Hygiène alimentaire
Santé
Santé Publique
Médecine - Divers
Industrie pharmaceutique
Biotechnologie
Tris Pharma Announces FDA Acceptance of NDA for Once-Nightly, Low-Sodium Oxybate Product for Narcolepsy and Idiopathic Hypersomnia
Source
Tris Pharma, Inc.
Émetteur
Business Wire
1.00
0
16/10/2025
Science
Psychiatrie
Médecine - Divers
Santé Publique
Hygiène alimentaire
Biotechnologie
Industrie pharmaceutique
Santé
Analyse de marché
Industrie
Tris Pharma Announces Acceptance of New Review Article Highlighting Challenges of Treating Moderate-to-Severe Acute Pain with Currently Available Drugs
Source
Tris Pharma, Inc.
Émetteur
Business Wire
1.00
0
28/08/2025
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Événements
Finance
Industrie
Tris Pharma Showcases a Novel Mechanism of Dual-NOP/MOP (NMR) Agonism for the Treatment of Moderate-to-Severe Acute Pain and Encores Positive Phase 3 Data at 2025 Annual PAINWeek Meeting in Las Vegas
Source
Tris Pharma, Inc.
Émetteur
Business Wire
1.00
0
12/06/2025
Psychiatrie
Science
Hygiène alimentaire
Médecine - Divers
Biotechnologie
Santé
Industrie pharmaceutique
Santé Publique
Industrie
Tris Pharma to Debut Positive Results of Intranasal (Snorting) Human Abuse Potential Study of Cebranopadol, an Investigational First-In-Class Oral Dual-NMR Agonist for the Treatment of Moderate-to-Severe Pain, at the 2025 CPDD Annual Meeting
Source
Tris Pharma, Inc.
Émetteur
Business Wire
1.00
0
01/05/2025
Événements
Biotechnologie
Santé Publique
Santé
Industrie pharmaceutique
Médecine - Divers
Tris Pharma to Unveil Positive Phase 3 Results including a Strong Safety Profile Showcasing the Potential of Cebranopadol, an Investigational First-in-Class Dual-NMR Agonist for the Treatment of Pain, at the 2025 ASRA Annual Meeting
Source
Tris Pharma, Inc.
Émetteur
Business Wire
1.00
0
01/04/2025
Événements
Biotechnologie
Santé Publique
Médecine - Divers
Santé
Industrie pharmaceutique
Tris Pharma to Present New Data at AAPM PainConnect Annual Meeting and Showcase Potential of Cebranopadol, a First-in-Class Investigational Dual-NMR Agonist for the Treatment of Pain
Source
Tris Pharma, Inc.
Émetteur
Business Wire
1.00
0
06/03/2025
Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain
Source
Tris Pharma, Inc.
Émetteur
Business Wire
1.00
0
28/01/2025
Tris Pharma Reports Positive Clinical Results of Intranasal Human Abuse Potential Study Indicating Low Abusability of Cebranopadol, an Investigational, First-in-Class Oral Dual-NMR Agonist for the Treatment of Moderate-to-Severe Pain
Source
Tris Pharma, Inc.
Émetteur
Business Wire
1.00
0
22/01/2025
Industrie
Oncologie
Santé
Médecine - Divers
Industrie pharmaceutique
Biotechnologie
Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain
Source
Tris Pharma, Inc.
Émetteur
Business Wire
1.00
0
19/11/2024
Psychiatrie
Santé
Santé Publique
Industrie pharmaceutique
Biotechnologie
Industrie
Tris Pharma Secures Additional ex-US Approvals to Expand Global Availability of Quillivant XR and QuilliChew ER for the Treatment of Attention Deficit Hyperactivity Disorder
Source
Tris Pharma, Inc.
Émetteur
Business Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0